Welcome to our dedicated page for Sionna Therapeutics news (Ticker: SION), a resource for investors and traders seeking the latest updates and insights on Sionna Therapeutics stock.
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis, and its news flow reflects ongoing progress in this specialized area of drug development. Company announcements frequently describe advances in its pipeline of small molecule nucleotide binding domain 1 (NBD1) stabilizers and complementary CFTR modulators designed to improve CFTR protein function.
News items for SION often cover key clinical milestones, such as initiation of the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis, and the Phase 1 trial assessing SION-451 in dual combinations with SION-2222 and SION-109 in healthy volunteers. Updates may include information on trial design, target patient populations, measures of CFTR function such as sweat chloride levels, and the rationale for combining NBD1 stabilizers with existing therapies.
Investors and observers can also find press releases on Phase 1 data, including reports that SION-719 and SION-451 were generally well tolerated and exceeded target exposure levels, as well as preclinical findings that NBD1 stabilizers increased the half-life of F508del-CFTR protein to levels seen with wild-type CFTR. Additional news highlights Sionna’s participation in scientific meetings like the North American Cystic Fibrosis Conference and appearances at healthcare and investor conferences.
This SION news page aggregates these disclosures, allowing readers to follow developments in Sionna’s CF-focused programs, track clinical and preclinical data releases, and monitor corporate updates that the company furnishes through press releases and related communications.
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has announced its upcoming participation at The Citizens Life Sciences Conference.
The company's management will deliver a presentation on Wednesday, May 7, 2025, at 12:30 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the "Events" section of Sionna's investor relations website at investors.sionnatx.com.
Sionna's mission centers on revolutionizing CF treatment by developing new medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The presentation recording will remain accessible on the company's website for 90 days following the event.
Sionna Therapeutics (SION) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its cystic fibrosis (CF) treatment programs. The company completed Phase 1 MAD dosing for SION-451 and plans the final MAD cohort for SION-719, with both compounds showing encouraging tolerability profiles. Interim data indicates potential clinical benefits for CF patients, with topline data expected in H1 2025.
The company successfully completed an upsized IPO raising $219 million in gross proceeds, extending their cash runway into 2028. Financial results show R&D expenses of $57.3 million and G&A expenses of $13.3 million for 2024, with a net loss of $61.7 million. The company plans to initiate NBD1 Phase 2a proof-of-concept trials and combination MAD trials in H2 2025, with topline data anticipated in mid-2026.
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cystic fibrosis (CF), has announced its participation in the 45th Annual TD Cowen Health Care Conference. The company's management will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET.
The presentation will be accessible through a live webcast on the company's investor relations website in the 'Events' section at investors.sionnatx.com. Interested parties who cannot attend the live presentation will have access to a replay, which will remain available for 90 days following the event.
Sionna's mission centers on revolutionizing CF treatment by developing new medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has successfully completed its upsized initial public offering (IPO). The company sold 12,176,467 shares of common stock at $18.00 per share, including 1,588,234 additional shares from the full exercise of the underwriters' option.
The IPO generated gross proceeds of approximately $219.2 million, before deducting underwriting discounts, commissions, and offering expenses. Trading of the shares began on the Nasdaq Global Market on February 7, 2025, under the ticker symbol 'SION'. The offering was jointly managed by Goldman Sachs & Co. , TD Cowen, Stifel, and Guggenheim Securities as book-running managers.
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has announced the pricing of its upsized initial public offering. The company is offering 10,588,233 shares of common stock at $18.00 per share, with an additional 30-day option for underwriters to purchase up to 1,588,234 shares.
Trading is scheduled to begin on the Nasdaq Global Market on February 7, 2025, under the ticker symbol 'SION'. The offering, expected to close on February 10, 2025, aims to raise approximately $191 million in gross proceeds before deducting expenses. Goldman Sachs & Co. , TD Cowen, Stifel, and Guggenheim Securities are serving as joint book-running managers for the IPO.